Fintel reports that on December 2, 2025, Goldman Sachs maintained coverage of Merck (NYSE:MRK) with a Buy recommendation.
We believe that the computing behemoth IBM (NYSE: IBM) is currently a better pick over the pharmaceuticals giant Merck (NYSE: MRK). The decision to invest often comes down to finding the best stocks ...
We believe that the computing behemoth IBM (NYSE: IBM) is currently a better pick over the pharmaceuticals giant Merck (NYSE: MRK). The decision to invest often comes down to finding the best stocks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results